Semaglutide sold as Ozempic and Wegovy generated over $48 billion in global sales in 2025. The STEP-1 trial showed 15% average weight loss. The SELECT trial proved a 20% reduction in cardiovascular events. Here are the most comprehensive semaglutide statistics for 2026.
Comprehensive obesity statistics for America in 2026. US adult obesity rate has fallen to 36.4% — the first sustained decline in decades, directly linked to GLP-1 medication adoption. Covers rates by state, demographic disparities, childhood obesity, $445 billion economic burden, and how tirzepatide and semaglutide are changing outcomes. Data sourced from CDC, Gallup, and peer-reviewed research. Updated July 2026.
The latest telehealth weight loss statistics for 2026 market size, patient outcomes, GLP-1 trends, and clinical data comparing virtual vs in-person care. Updated July 2026.
The most comprehensive GLP-1 statistics resource for 2026. Covers US obesity rates, semaglutide and tirzepatide clinical data, market size, prescription trends, pricing changes, and what the latest research shows. Updated July 2026
Wondering what your first week on Mounjaro (tirzepatide) will feel like? Learn about common first-week side effects, including nausea, constipation, bloating, fatigue, appetite changes, and dizziness. This physician-reviewed guide explains what to expect during your first 7 days, practical ways to reduce side effects, and when to contact your healthcare provider.
This guide covers what clinical trial data actually shows about weight regain after stopping tirzepatide, why it happens, how fast it tends to occur, and what you can do to protect your progress.
Learn about common, rare, and long-term tirzepatide side effects, including nausea, constipation, injection site reactions, sulfur burps, weight regain after stopping treatment, and symptom timelines. This physician-reviewed guide from GoalBMI Wellness explains what to expect, when side effects typically improve, and when to contact your healthcare provider.
Thinking about stopping BPC-157? Learn whether BPC-157 should be tapered, what happens after discontinuation, whether symptoms may return, and what healthcare professionals recommend before making changes to your peptide therapy.
Semaglutide and tirzepatide are two of the most popular weight loss medications available today. Learn how they compare for weight loss, dosing, treatment timelines, before and after results, side effects, and which option may be appropriate for eligible patients.
